Seeking Alpha

Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier ...
Insurancenewsnet.com

FEDMED to Provide Insurance Coverage for Decipher® Prostate Cancer Test

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher ® prostate cancer test to FEDMED Payors. FEDMED is ...
Nasdaq

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

Findings published in European Urology Oncology suggest genomic classifier scores are highly correlated with PSMA PET upstaging of prostate cancer in those with high-risk and very high-risk disease ...
Business Wire

New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...
Nasdaq

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...
Seeking Alpha

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic ...
Business Insider

Decipher Prostate RP Identifies Patients Likely to Benefit from Hormonal Therapy in Men with Recurrent Prostate Cancer

SAN DIEGO, Feb. 18, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced ...
Insurancenewsnet.com

Decipher® Genomic Prostate Cancer Test to Be Featured in Multiple Presentations and Events at Upcoming AUA Annual Meeting

Abstract Title: "Independent validation of a genomic classifier in an at risk population of men conservatively managed after radical prostatectomy" Several educational events will cover ground on the ...
Morningstar

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...
News Medical

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
Business Insider

Decipher Biosciences Announces Publication of a Prospective Clinical Study Demonstrating that the Use of Decipher Prostate RP Guides Post-Operative Management Decisions and ...

SAN DIEGO, Dec. 16, 2019 /PRNewswire/ -- Decipher Biosciences, a commercial stage precision oncology company initially focused on urologic cancers, today announced that recent findings from a ...